What's Happening?
Researchers at Michigan Medicine have developed an experimental drug, DT-109, which has shown promise in reversing severe fatty liver disease, specifically metabolic dysfunction-associated steatohepatitis (MASH), in animal studies. Published in The Journal
of Clinical Investigation, the study highlights how DT-109, a glycine-based tripeptide, restores gut health by protecting the gut epithelial barrier. This action reduces the systemic influx of harmful microbial products that contribute to MASH. The drug was effective in both mice and nonhuman primates, reducing levels of the bacterium Clostridium perfringens and lowering ammonia production, which in turn strengthened the intestinal barrier and reduced liver inflammation.
Why It's Important?
MASH is a serious form of fatty liver disease affecting about 7% of the global population, with potential progression to cirrhosis, liver cancer, and liver failure. Current treatment options are limited, making the development of DT-109 significant. By targeting the gut-liver axis, DT-109 offers a novel therapeutic approach that could improve liver and heart health. The drug's potential extends beyond MASH, as it may also reduce atherosclerosis plaques and prevent vascular calcification, indicating possible applications in treating cardiovascular diseases. The findings could lead to new treatment avenues for other conditions linked to intestinal barrier breakdown, such as inflammatory bowel disease.
What's Next?
Future research will focus on additional testing to move DT-109 into clinical trials, assessing its safety and effectiveness in humans. The University of Michigan has patented the compound and licensed it to Diapin Therapeutics, which is continuing its development. The study's promising results in nonhuman primates, whose liver biology closely resembles humans, suggest a strong potential for successful human trials. Researchers are optimistic about DT-109's ability to provide a safe and effective therapy for MASH and related conditions, potentially transforming treatment protocols for these diseases.
